GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » Debt-to-Revenue

Allergy Therapeutics (Allergy Therapeutics) Debt-to-Revenue

: 0.15 (As of Dec. 2023)
View and export this data going back to 2004. Start your Free Trial

Debt-to-Revenue measures a company's ability to pay off its debt.

Allergy Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.22 Mil. Allergy Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.25 Mil. Allergy Therapeutics's annualized Revenue for the quarter that ended in Dec. 2023 was $84.99 Mil. Allergy Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.15.


Allergy Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Allergy Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.16 0.13 0.15 0.60

Allergy Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.22 0.12 0.91 0.15

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allergy Therapeutics Debt-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Debt-to-Revenue falls into.



Allergy Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Allergy Therapeutics's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.277 + 43.164) / 75.236
=0.60

Allergy Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.215 + 10.253) / 84.992
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Allergy Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics (Allergy Therapeutics) Business Description

Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (Allergy Therapeutics) Headlines